ABOUT
PolyNova Cardiovascular, Inc. is a private, for-profit, start-up medical device company, incorporated in Delaware and operating in New York State. PolyNova is housed in the Long Island High Technology Incubator on the campus of Stony Brook University, Stony Brook, NY.
PolyNova was established in 2012 as a commercial spin-off from years of state, VC, and federally funded academic research into polymeric heart valves. The mission of PolyNova is to successfully bring to market an innovative, safe and effective polymer-based Transcatheter Aortic Valve Replacement (TAVR) for the treatment of aortic stenosis (AS). Our vision is to develop a family of products based upon our polymer technology for the treatment of valvular heart disease.
Management Team
Dr. Marvin J Slepian, MD, JD CEO and Chairman, Co-founder
Regents’ Professor – Medicine/Cardiology and Biomedical Engineering – U Arizona >40 yrs inventor – Biodegradable stents, Polymer paving, blood compatibility systems, wearable technologies, transient electronics, medical devices, total artificial heart Founder >15 Co. (Focal FOCL NASDAQ, Hansen HSN NASDAQ, Syncardia) with Operating experience as CEO, Chairman or Member BOD. Appointed member PPAC USPTO DOC
Dr. Danny Bluestein, PhD CSO, Co-founder
Distinguished Professor of Biomedical Engineering at Stony Brook University, NY. World-renowned researcher in biofluid mechanics, computational modeling, cardiovascular devices design and optimization, and the study of cardiovascular pathologies. > 25 yrs expertise
Dr. Leonard Pinchuk, PhD Scientific Advisory Board
Serial inventor and entrepreneur with 138 issued U.S. Patents and more than 100 publications. Founder of 10 companies. Expertise in Biomaterials
PolyNova does not currently market or sell any medical devices. The FDA has not approved any PolyNova products for use in the United States of America. PolyNova does not hold any CE Marks. This website may contain forward-looking statements and is for informational purposes only.